NU 578 Units 1–5 Exam (2026/2027) | University of South
Alabama Advanced Pharmacology – 120+ Mixed-Format
Questions with Verified Answers & Clinical Rationales for
MSN, APRN, DNP | INSTANT PDF DOWNLOAD
Introduction
This NU 578 Units 1–5 Exam preparation guide contains over 120 practice questions
covering foundational pharmacology principles through advanced clinical application. The
guide includes a mix of standard multiple-choice questions, clinical scenario-based
questions, select-all-that-apply, and ordered-response formats, mirroring the structure of
actual University of South Alabama advanced pharmacology unit exams. All answers are
presented in bold italic for rapid identification, accompanied by detailed italic explanations
that reinforce pharmacologic reasoning and clinical decision-making. Major content areas
include pharmacokinetics (absorption, distribution, metabolism, excretion, first-pass effect,
half-life, steady state), pharmacodynamics (receptor binding, agonists/antagonists,
therapeutic index, potency, efficacy, drug interactions, CYP450 inducers/inhibitors), DEA
drug scheduling (Schedules I–V), autonomic nervous system pharmacology (cholinergic
agonists/antagonists, adrenergic agonists/antagonists), central nervous system drugs
(Parkinson disease agents, antidepressants – SSRIs, MAOIs, TCAs, anticonvulsants,
benzodiazepines, opioids, antipsychotics), cardiovascular pharmacology (antihypertensives
– ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, diuretics; antiarrhythmics;
digoxin; statins), antibiotic therapy (penicillins, cephalosporins, fluoroquinolones,
macrolides, tetracyclines, aminoglycosides, vancomycin; resistance mechanisms; adverse
effects including ototoxicity, nephrotoxicity, tendon rupture, C. diff colitis), endocrine
pharmacology (insulin types, oral hypoglycemics – metformin, sulfonylureas, GLP-1
agonists, SGLT2 inhibitors; thyroid medications – levothyroxine, methimazole;
corticosteroids), pregnancy safety categories (PLLR – Pregnancy and Lactation Labeling
Rule), drug toxicity and overdose management (organophosphate poisoning,
acetaminophen overdose, opioid overdose – naloxone, digoxin toxicity – Digibind), adverse
drug reaction identification (Steven-Johnson syndrome, DRESS syndrome, anaphylaxis),
polypharmacy in elderly patients, and pharmacogenomics (CYP2D6, CYP2C19 variants).
This guide is ideal for MSN, APRN, DNP, and NP students preparing for unit exams, final
exams, pharmacology certification, or clinical practice.
,Unit 1: Foundational Pharmacology Principles – Pharmacokinetics,
Pharmacodynamics, Drug Scheduling (Questions 1–30)
Standard Multiple-Choice Questions
Q1. A drug with a half-life of 12 hours is administered intravenously. Approximately how
many hours will it take to reach steady state?
A) 24 hours
B) 36 hours
C) 48 hours
D) 60 hours
Answer: D
*Explanation: Steady state is reached after approximately 4–5 half-lives. 12 hours × 4 = 48
hours; 12 hours × 5 = 60 hours. The standard answer is approximately 48–60 hours, with 60
hours representing 5 half-lives for complete steady state.*
Q2. Which route of administration bypasses the first-pass effect?
A) Oral
B) Sublingual
C) Rectal
D) Both B and C
Answer: D
Explanation: Sublingual and rectal routes bypass the first-pass effect because drugs
absorbed through these routes enter systemic circulation directly without passing
through the liver first. Oral administration (A) is subject to first-pass metabolism in
the liver.
Q3. The therapeutic index (TI) of a drug is calculated as:
A) ED50 / TD50
B) TD50 / ED50
C) ED50 × TD50
D) LD50 / ED50
Answer: B
*Explanation: Therapeutic index = TD50 (median toxic dose) / ED50 (median effective
,dose) – or LD50/ED50 in animal studies. A larger TI indicates a wider margin of safety; a
narrow TI (e.g., digoxin, warfarin, phenytoin) requires therapeutic drug monitoring.*
Q4. A drug that binds to a receptor and produces a maximal response equal to that of an
endogenous agonist is called a:
A) Partial agonist
B) Antagonist
C) Full agonist
D) Inverse agonist
Answer: C
Explanation: A full agonist binds to a receptor and produces a maximal response
(100% efficacy). A partial agonist (A) produces a submaximal response even at full
receptor occupancy. An antagonist (B) blocks the receptor without activating it.
Q5. Which CYP450 enzyme is responsible for metabolizing approximately 25–30% of all
clinically used drugs?
A) CYP1A2
B) CYP2C9
C) CYP2D6
D) CYP3A4
Answer: D
Explanation: CYP3A4 is the most abundant and important CYP450 enzyme,
metabolizing approximately 25–30% of all drugs. It is involved in the metabolism of
many drugs including statins, calcium channel blockers, benzodiazepines, and
immunosuppressants.
Q6. A patient is taking warfarin and begins taking cimetidine (a CYP450 inhibitor). The
nurse practitioner should anticipate:
A) Decreased INR, requiring increased warfarin dose
B) Increased INR, requiring decreased warfarin dose
C) No change in INR
D) Increased risk of thrombosis
Answer: B
Explanation: Cimetidine inhibits CYP450 enzymes (particularly CYP2C9, CYP1A2,
CYP2D6, CYP3A4) that metabolize warfarin. Inhibition decreases warfarin
metabolism, increasing warfarin concentration and anticoagulant effect (INR
increases). Warfarin dose must be reduced to prevent bleeding.
, Q7. A drug with zero-order kinetics:
A) Is eliminated at a constant rate regardless of concentration
B) Is eliminated at a rate proportional to concentration (first-order)
C) Reaches steady state in one half-life
D) Is always administered intravenously
Answer: A
Explanation: Zero-order kinetics means a constant amount of drug is eliminated per
unit time regardless of drug concentration (e.g., phenytoin, ethanol, high-dose
aspirin). This increases toxicity risk because small dose increases can cause
disproportionate concentration rises. First-order kinetics (B) is more common.
Q8. Bioavailability refers to:
A) The amount of drug bound to plasma proteins
B) The fraction of administered drug that reaches systemic circulation unchanged
C) The time required for drug concentration to decrease by 50%
D) The volume of distribution of a drug
Answer: B
*Explanation: Bioavailability (F) is the fraction of an administered dose that reaches
systemic circulation unchanged. IV administration has 100% bioavailability. Oral
bioavailability is affected by absorption and first-pass metabolism.*
Q9. Which of the following factors INCREASES the volume of distribution (Vd) of a drug?
A) High protein binding
B) High lipid solubility
C) Low lipid solubility
D) High polarity
Answer: B
Explanation: High lipid solubility allows drugs to cross cell membranes and
distribute into tissues (including adipose tissue), increasing Vd. High protein binding
(A) tends to keep drugs in the vascular space, decreasing Vd. Low lipid
solubility/high polarity (C, D) limits tissue distribution, decreasing Vd.
Q10. A drug with a narrow therapeutic index requires:
A) Less frequent monitoring
B) Therapeutic drug monitoring (TDM) to maintain safe levels
C) Higher initial loading doses
D) Oral administration only
Alabama Advanced Pharmacology – 120+ Mixed-Format
Questions with Verified Answers & Clinical Rationales for
MSN, APRN, DNP | INSTANT PDF DOWNLOAD
Introduction
This NU 578 Units 1–5 Exam preparation guide contains over 120 practice questions
covering foundational pharmacology principles through advanced clinical application. The
guide includes a mix of standard multiple-choice questions, clinical scenario-based
questions, select-all-that-apply, and ordered-response formats, mirroring the structure of
actual University of South Alabama advanced pharmacology unit exams. All answers are
presented in bold italic for rapid identification, accompanied by detailed italic explanations
that reinforce pharmacologic reasoning and clinical decision-making. Major content areas
include pharmacokinetics (absorption, distribution, metabolism, excretion, first-pass effect,
half-life, steady state), pharmacodynamics (receptor binding, agonists/antagonists,
therapeutic index, potency, efficacy, drug interactions, CYP450 inducers/inhibitors), DEA
drug scheduling (Schedules I–V), autonomic nervous system pharmacology (cholinergic
agonists/antagonists, adrenergic agonists/antagonists), central nervous system drugs
(Parkinson disease agents, antidepressants – SSRIs, MAOIs, TCAs, anticonvulsants,
benzodiazepines, opioids, antipsychotics), cardiovascular pharmacology (antihypertensives
– ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, diuretics; antiarrhythmics;
digoxin; statins), antibiotic therapy (penicillins, cephalosporins, fluoroquinolones,
macrolides, tetracyclines, aminoglycosides, vancomycin; resistance mechanisms; adverse
effects including ototoxicity, nephrotoxicity, tendon rupture, C. diff colitis), endocrine
pharmacology (insulin types, oral hypoglycemics – metformin, sulfonylureas, GLP-1
agonists, SGLT2 inhibitors; thyroid medications – levothyroxine, methimazole;
corticosteroids), pregnancy safety categories (PLLR – Pregnancy and Lactation Labeling
Rule), drug toxicity and overdose management (organophosphate poisoning,
acetaminophen overdose, opioid overdose – naloxone, digoxin toxicity – Digibind), adverse
drug reaction identification (Steven-Johnson syndrome, DRESS syndrome, anaphylaxis),
polypharmacy in elderly patients, and pharmacogenomics (CYP2D6, CYP2C19 variants).
This guide is ideal for MSN, APRN, DNP, and NP students preparing for unit exams, final
exams, pharmacology certification, or clinical practice.
,Unit 1: Foundational Pharmacology Principles – Pharmacokinetics,
Pharmacodynamics, Drug Scheduling (Questions 1–30)
Standard Multiple-Choice Questions
Q1. A drug with a half-life of 12 hours is administered intravenously. Approximately how
many hours will it take to reach steady state?
A) 24 hours
B) 36 hours
C) 48 hours
D) 60 hours
Answer: D
*Explanation: Steady state is reached after approximately 4–5 half-lives. 12 hours × 4 = 48
hours; 12 hours × 5 = 60 hours. The standard answer is approximately 48–60 hours, with 60
hours representing 5 half-lives for complete steady state.*
Q2. Which route of administration bypasses the first-pass effect?
A) Oral
B) Sublingual
C) Rectal
D) Both B and C
Answer: D
Explanation: Sublingual and rectal routes bypass the first-pass effect because drugs
absorbed through these routes enter systemic circulation directly without passing
through the liver first. Oral administration (A) is subject to first-pass metabolism in
the liver.
Q3. The therapeutic index (TI) of a drug is calculated as:
A) ED50 / TD50
B) TD50 / ED50
C) ED50 × TD50
D) LD50 / ED50
Answer: B
*Explanation: Therapeutic index = TD50 (median toxic dose) / ED50 (median effective
,dose) – or LD50/ED50 in animal studies. A larger TI indicates a wider margin of safety; a
narrow TI (e.g., digoxin, warfarin, phenytoin) requires therapeutic drug monitoring.*
Q4. A drug that binds to a receptor and produces a maximal response equal to that of an
endogenous agonist is called a:
A) Partial agonist
B) Antagonist
C) Full agonist
D) Inverse agonist
Answer: C
Explanation: A full agonist binds to a receptor and produces a maximal response
(100% efficacy). A partial agonist (A) produces a submaximal response even at full
receptor occupancy. An antagonist (B) blocks the receptor without activating it.
Q5. Which CYP450 enzyme is responsible for metabolizing approximately 25–30% of all
clinically used drugs?
A) CYP1A2
B) CYP2C9
C) CYP2D6
D) CYP3A4
Answer: D
Explanation: CYP3A4 is the most abundant and important CYP450 enzyme,
metabolizing approximately 25–30% of all drugs. It is involved in the metabolism of
many drugs including statins, calcium channel blockers, benzodiazepines, and
immunosuppressants.
Q6. A patient is taking warfarin and begins taking cimetidine (a CYP450 inhibitor). The
nurse practitioner should anticipate:
A) Decreased INR, requiring increased warfarin dose
B) Increased INR, requiring decreased warfarin dose
C) No change in INR
D) Increased risk of thrombosis
Answer: B
Explanation: Cimetidine inhibits CYP450 enzymes (particularly CYP2C9, CYP1A2,
CYP2D6, CYP3A4) that metabolize warfarin. Inhibition decreases warfarin
metabolism, increasing warfarin concentration and anticoagulant effect (INR
increases). Warfarin dose must be reduced to prevent bleeding.
, Q7. A drug with zero-order kinetics:
A) Is eliminated at a constant rate regardless of concentration
B) Is eliminated at a rate proportional to concentration (first-order)
C) Reaches steady state in one half-life
D) Is always administered intravenously
Answer: A
Explanation: Zero-order kinetics means a constant amount of drug is eliminated per
unit time regardless of drug concentration (e.g., phenytoin, ethanol, high-dose
aspirin). This increases toxicity risk because small dose increases can cause
disproportionate concentration rises. First-order kinetics (B) is more common.
Q8. Bioavailability refers to:
A) The amount of drug bound to plasma proteins
B) The fraction of administered drug that reaches systemic circulation unchanged
C) The time required for drug concentration to decrease by 50%
D) The volume of distribution of a drug
Answer: B
*Explanation: Bioavailability (F) is the fraction of an administered dose that reaches
systemic circulation unchanged. IV administration has 100% bioavailability. Oral
bioavailability is affected by absorption and first-pass metabolism.*
Q9. Which of the following factors INCREASES the volume of distribution (Vd) of a drug?
A) High protein binding
B) High lipid solubility
C) Low lipid solubility
D) High polarity
Answer: B
Explanation: High lipid solubility allows drugs to cross cell membranes and
distribute into tissues (including adipose tissue), increasing Vd. High protein binding
(A) tends to keep drugs in the vascular space, decreasing Vd. Low lipid
solubility/high polarity (C, D) limits tissue distribution, decreasing Vd.
Q10. A drug with a narrow therapeutic index requires:
A) Less frequent monitoring
B) Therapeutic drug monitoring (TDM) to maintain safe levels
C) Higher initial loading doses
D) Oral administration only
